Huntington Disease Foundation to Assess Six of CHDI, Inc.'s Drugs for Potential to Delay or Slow Progression of the Disease

LAS VEGAS, Jan. 24, 2008 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (OTCBB:SPHC), a biopharmaceutical company focused on bringing innovative life-saving drugs to suffering patients, has entered into an agreement with CHDI Foundation, Inc. CHDI is a nonprofit organization pursuing the discovery and development of drugs to delay or slow the progression of Huntington's disease (HD), an inherited disorder that causes programmed degeneration of brain cells. Per the agreement, Samaritan will grant CHDI an 18-month non-exclusive license to evaluate the usefulness of six of Samaritan's Alzheimer's drugs, SP-233, Sp-sc4, Sp-sc7, Sp-04, Sp-04m, and Sp-08, as possible therapeutics for HD. CHDI will pay for the cost of this evaluation and Samaritan will retain all rights in its compounds.